Urologix, Inc. (ULGX) Stock Price & Analysis
Urologix, Inc. (ULGX) closed at USD 0 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0; the Oct 22, 2026 session ranged USD 0–0 on volume of 125 shares. Market capitalization is $2,181, with a 52-week range of USD 0–0.01 (PNK). Source: Nexqual, retrieved October 23, 2026 at 18:52 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ULGX.md
Key facts (ULGX)
- Analysts: None.
- Total return with dividends: 1Y +0.0% vs S&P 500 +14.4%; 5Y -50.0% vs S&P 500 +77.0%.
Analysts (ULGX)
Consensus None.
Total return (dividends reinvested) (ULGX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +0.0% | -50.0% |
| S&P 500 (SPY) | +14.4% | +77.0% |
| Per year | +0.0% | -13.0% |
| Volatility (annualized) | 98.6% | 185.2% |
| Max drawdown | -50.0% (Feb 2026→Mar 2026) | -95.0% (Oct 2021→Apr 2023) |
ULGX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Jun 2013) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 23, 2026 at 18:52 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.01 |
| Volume | 125 shares |
| Market Cap | $2,181 |
| Exchange | PNK |
Technical Analysis (ULGX)
Nexqual's technical model rates ULGX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 18:52 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (ULGX)
Wall Street analysts rate ULGX "None", per Nexqual as of October 23, 2026 at 18:52 UTC.
| Consensus Rating | None |
|---|
Earnings (ULGX)
Source: Nexqual, October 23, 2026 at 18:52 UTC.
Financials & Fundamentals (ULGX)
| Total Revenue | $12.00M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -16.70% |
| Gross Margin | +47.13% |
| Operating Margin | -5.56% |
| Profit Margin | -38.90% |
| Current Ratio | 0.56 |
| Total Cash | $492,000 |
| Total Debt | $5.33M |
Source: Nexqual, October 23, 2026 at 18:52 UTC.
Financial Health Score (ULGX)
Nexqual rates Urologix, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 18:52 UTC.
| Growth | Strong — Revenue +15% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $492K cash vs $5M debt |
| Cash Flow | Weak — Operating cash flow -$263K (TTM) |
| Efficiency | Mixed — No data |
Ownership (ULGX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 21.82M |
| Short % of Float | +0.30% |
Source: Nexqual, October 23, 2026 at 18:52 UTC.
Leadership (ULGX)
Urologix, Inc. is led by Bryon Merade, Chairman & CEO, per Nexqual as of October 23, 2026 at 18:52 UTC.
| Chairman & CEO | Bryon Merade |
|---|
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATEC | Alphatec Holdings, Inc. | USD 11.18 | ▼ 1.63% |
| BFLY | Butterfly Network, Inc. | USD 6.7 | ▼ 1.62% |
| ESTA | Establishment Labs Holdings Inc | USD 64.25 | ▲ 1.15% |
| INSP | Inspire Medical Systems, Inc. | USD 71.06 | ▼ 2.2% |
| ALMR | Alamar Biosciences, Inc. | USD 30.7 | ▲ 3.3% |
| AXGN | AxoGen, Inc. | USD 37.73 | ▲ 2.86% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 18:52 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt